Patents by Inventor David Will
David Will has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070173503Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.Type: ApplicationFiled: August 31, 2006Publication date: July 26, 2007Applicant: Aventis Pharma S.A.Inventors: Swen Hoelder, Karl Schoenafinger, David Will, Hans Matter, Gunter Muller, Cecile Combeau, Christine Delaisi, Anke Steinmetz, Ingrid Sassoon
-
Publication number: 20070149776Abstract: The present invention is directed to the preparation of novel compounds useful in the treatment of hyperlipidemia, arteriosclerosis, hypercholesterolemia, and other related metabolic disorders.Type: ApplicationFiled: November 20, 2006Publication date: June 28, 2007Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Andreas LINDENSCHMIDT, David WILL, Gerhard JAEHNE, Theodor WOLLMANN, Wendelin FRICK, Bernd JUNKER, David RIGAL, Guenter BILLEN, Heiner JENDRALLA
-
Publication number: 20070108650Abstract: A method of forming a composite article by injecting at least two composite materials comprising metal carbides into a mold to form a green compact is disclosed. The composite materials may be metal powders comprising a binder metal, a hard particle. The composite material may further comprise a plastic binder. The two different composite materials are injected into the mold to form the green compact. Additionally, the composite materials may be injected through a die before entering the mold. In a specific embodiment, the die forms at least one internal channel within the green compact.Type: ApplicationFiled: October 24, 2006Publication date: May 17, 2007Inventors: Prakash Mirchandani, David Wills, Michale Waller, Jeffrey Weigold, Billy Swearengin
-
Publication number: 20070088041Abstract: The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3?(glycogen synthase kinase-3?).Type: ApplicationFiled: October 24, 2006Publication date: April 19, 2007Applicant: Sanofi-aventis Deutschland GmbHInventors: Swen Hoelder, Karl Schoenafinger, David Will, Hans Matter, Guenter Mueller, Martin Bossart
-
Publication number: 20070042217Abstract: Embodiments of the present invention include methods of producing a composite article. A method comprises introducing a first powdered metal grade from a feed shoe into a first portion of a cavity in a die and a second powdered metal grade from the feed shoe into a second portion of the cavity, wherein the first powder metal grade differs from the second powdered metal grade in chemical composition or particle size. Further methods are also provided. Embodiments of the present invention also comprise composite inserts for material removal operations. The composite inserts may comprise a first region and a second region, wherein the first region comprises a first composite material and the second region comprises a second composite material.Type: ApplicationFiled: August 18, 2005Publication date: February 22, 2007Inventors: X. Fang, David Wills, Prakash Mirchandani
-
Publication number: 20060269374Abstract: The present invention relates to embodiments of a cutting tool holder (10) having at least one insert pocket (13), wherein at least one insert pocket comprises a side surface (15) and at least one antirotation stop (16) protruding from the side surface. The antirotation stop may comprise at least two substantially planar surfaces. In certain embodiments, the cutting tool holder may have a pocket which comprises a bottom surface and an antirotation stop having three substantially planar surfaces that are substantially perpendicular to the bottom surface. The antirotation stop may be integral to the tool holder or may be produced separately and attached, either permanently or temporarily, to the tool holder. Embodiments may further comprise additional antirotation stops is desired by the machining application.Type: ApplicationFiled: March 2, 2004Publication date: November 30, 2006Applicant: TDY INDUSTRIES, INC.Inventors: Jean-Luc Dufour, X. Fang, David Wills
-
Publication number: 20060245837Abstract: The present invention relates to embodiments of a cutting tool holder having at least one insert pocket, wherein at least one insert pocket comprises a side surface and at least one antirotation stop protruding from the side surface. The antirotation stop may comprise at least two substantially planar surfaces. In certain embodiments, the cutting tool holder may have a pocket which comprises a bottom surface and an antirotation stop having three substantially planar surfaces that are substantially perpendicular to the bottom surface. The antirotation stop may be integral to the tool holder or may be produced separately and attached, either permanently or temporarily, to the tool holder. Embodiments may further comprise additional antirotation stops if desired by the machining application.Type: ApplicationFiled: April 15, 2003Publication date: November 2, 2006Inventors: Jean-Luc Dufour, X. Fang, David Wills
-
Publication number: 20060247503Abstract: A method and system for determining an increased probability of injury to a person. The method and system includes determining at least one factor indicative of a propensity to anatomical failure, determining a probability of an anatomical failure occurring as a function of the at least one factor, the anatomical failure being correlated to an injury, and predicting an increased probability of anatomical failure about to occur as a function of the determined probability, the at least one factor, and a period of time of a condition.Type: ApplicationFiled: April 29, 2005Publication date: November 2, 2006Inventors: Orlando Sellers, David Will
-
Publication number: 20060051618Abstract: The present invention relates to the PVD coated tungsten carbide (WC) based cemented cutting inserts with ruthenium (Ru) as a key chemical element, or a key feature, in the cobalt (Co)-based binder phase, particularly useful for machining today's mold & die materials. In the Ru—Co mixed binder phase in the tungsten carbide substrate, the ratio of Ru/Co is at least 3%, by weight. The Ru-featured carbide cutting insert provided in this invention is PVD coated with one or more layers by a modern PVD coating technology. The development of the PVD coated Ru-featured carbide cutting inserts provided in this invention is based on a discovery that the unique combination of PVD coating techniques and Ru-featured carbide cutting inserts demonstrates superior machining performance in today's mold & die machining applications.Type: ApplicationFiled: August 20, 2004Publication date: March 9, 2006Inventors: Gilles Festeau, X. Fang, David Wills
-
Publication number: 20050260454Abstract: The present invention relates to ceramic cutting tools, such as, a aluminum oxide with zirconium oxide ceramic cutting tool with diffusion bonding enhanced layer and CVD coatings, particularly useful for machining modem metal materials. The method comprises a chemical reaction with a mixture including nitrogen and aluminum chloride introduced to form a diffusion bonding enhanced layer between the ceramic substrate and the CVD coatings. Thus formed diffusion bonding is highly adherent to the aluminum oxide with zirconium oxide ceramic substrate and significantly enhances the CVD coating properties, and thus improving the machining performance in terms of the tool life of zirconium-based aluminum oxide with zirconium oxide ceramic cutting tools.Type: ApplicationFiled: May 19, 2004Publication date: November 24, 2005Inventors: X. Fang, David Wills, Gilles Festeau
-
Publication number: 20050165058Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W—U—V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.Type: ApplicationFiled: January 19, 2005Publication date: July 28, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Marc Nazare, David Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
-
Publication number: 20050143419Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: July 7, 2004Publication date: June 30, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, David Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Publication number: 20050084342Abstract: A cutting insert for milling operations, such as, face milling, slot milling, plunge milling, and ramping operations. The cutting insert exhibits a combination of favorable cutting edge strength, and unique cutting edge geometry, thus, allowing milling operations at relatively high feed rates. The cutting insert includes at least four cutting edges, wherein at least one of the cutting edges is a convex cutting edge. Certain embodiments of square cutting inserts will have four convex cutting edges which may be connected by nose corners. The convex cutting edge may comprise at least one of a circular arc, a portion of an ellipse, a portion of a parabola, a multi-segment spline curve, a straight line, or combinations of these. Wherein the convex cutting edge comprises a circular arc, the circular arc may have a radius greater than or equal to two times a radius of the largest circle that may be inscribed on the top surface.Type: ApplicationFiled: October 15, 2003Publication date: April 21, 2005Inventors: Gilles Festeau, Jean-Luc Dufour, X. Fang, David Wills
-
Publication number: 20050043302Abstract: The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor Vila is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.Type: ApplicationFiled: August 26, 2004Publication date: February 24, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Marc Nazare, Melanie Essrich, David Will, Hans Matter, Kurt Ritter, Volkmar Wehner
-
Publication number: 20050026918Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.Type: ApplicationFiled: November 19, 2003Publication date: February 3, 2005Inventors: Swen Holder, Thorsten Naumann, Karl Schonafinger, David Will, Hans Matter, Gunther Muller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi, Cecile Combeau, Ingrid Sassoon, Anke Steinmetz
-
Publication number: 20050020523Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.Type: ApplicationFiled: December 11, 2003Publication date: January 27, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Eugen Uhlmann, Anuschirwan Peyman, David Will, Esther Chang, Kathleen Pirollo, Antonina Rait
-
Publication number: 20050009828Abstract: The present invention relates to compounds of the formula I wherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: May 19, 2004Publication date: January 13, 2005Applicant: Aventis Pharma DeutschlandInventors: Marc Nazare, Volkmar Wehner, David Will, Kurt Ritter, Matthias Urmann, Hans Matter
-
Publication number: 20050009073Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.Type: ApplicationFiled: June 2, 2004Publication date: January 13, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Eugen Uhlmann, Gerhard Breipohl, David Will
-
Publication number: 20030203896Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.Type: ApplicationFiled: January 27, 2003Publication date: October 30, 2003Inventors: Anurschirwan Peyman, David Will, Thomas R Gadek, Jochen Knolle, Robert McDowell, Jean-Francois Gourvest, Jean-Marie Ruxer
-
Publication number: 20030078585Abstract: An apparatus for holding a first portion of a bone and a second portion of a bone together for the bone to heal. A method for holding a first portion of a bone and a second portion of a bone together for the bone to heal. A suture. A grommet for a bone. A method for securing a suture through a bone.Type: ApplicationFiled: November 25, 2002Publication date: April 24, 2003Inventors: Greg A. Johnson, James F. Antaki, James A. Magovern, Matthew R. Frushell, Thomas David Will, John Andrew Holmes